Sentence examples for bone scintigraphy using the from inspiring English sources

This review attempts to optimise the diagnostic effectiveness of bone scintigraphy using the hybrid SPECT/CT technique in relation to the diagnostic clues provided by other imaging modalities, discusses the appropriate clinical indications, optimal scintigraphic procedures and illustrates updated image pattern-oriented reporting.

Radionuclide bone scintigraphy using radiolabeled bisphosphonates is the mainstay for the detection of skeletal metastases in patients with various tumoral entities.

Of the available adjunctive diagnostic imaging modalities, radionuclide bone scintigraphy using a TPBS protocol is the most sensitive and specific for detecting abnormalities commonly seen with this condition-classically, increased periarticular uptake on delayed phase of TPBS, with variable increased uptake on perfusion phases, depending on chronicity.

To date, bone scintigraphy using MDP or HMDP has been the cornerstone in the evaluation of newly diagnosed high-risk prostate cancer patients, since it is a widely available and inexpensive whole-body imaging technique that allows the reliable ruling out of skeletal involvement in a single examination, due to its high sensitivity.

Bone scintigraphy using 99mTc-methylene diphosphonate remains the primary clinical imaging tool for detection of metastases; however, it is not tumor specific.

Bone scintigraphy using radiolabeled bisphosphonates is of great importance in the management of these patients; however, its main drawback is its low overall accuracy, due to the nonspecific uptake in sites of increased bone turnover.

Greater accuracy values than those observed in radionuclide bone scintigraphy using technetium-99m-labeled samples have been reported in the detection of skeletal metastases from different primary tumors.

Radionuclide bone scintigraphy using labeled bisphosphonates, either performed with planar, SPECT, or SPECT/CT acquisition, remains the most widely available and simple technique for the early detection of bone metastases in prostate cancer patients at diagnosis.

As early as in 1972, the US Food and Drug Administration FDAapprovedved the first positron-emitting radiotracer, 18F sodium fluoride (18F NaF), for bone scintigraphy using planar gamma camera imaging.

Gerety, E. L. et al. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.

In all patients, bone scintigraphy using 99mTc-3,3-diphosphono-1,2-propanedicarboxylic acid (99mTc-DPD) (Teceos, Behringwerke AG, Marburg) was performed.